Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millipore Posts Revenues Of $407.9 Million For Q1 2009
Looking forward for the full year 2009, the company anticipates that its reported revenues will be between a 1% decline and 1% growth over 2008. Excluding a 4%
Looking forward for the full year 2009, the company anticipates that its reported revenues will be between a 1% decline and 1% growth over 2008. Excluding a 4%
Operating expenses decreased to $10.6 million for the first quarter of 2009 from $12.0 million for the first quarter of 2008, primarily as a result of a strategic
Cambrex, a provider of products and services to accelerate the development and commercialization of small molecule therapeutics, has reported increase in net income to $4.7m in the first
SOCMA and partners in federal government are working together to bring the latest information and guidance with regards to swine flu out break in the US and Mexico.
The cooperative R&D agreement (CRADA) is for a two-year study that will utilize the Biojector 2000 in human subjects. An additional objective is to promote a partnering relationship
The Prescription Drug User Fee Act date is the target date for the FDA to complete its review of the Fampridine-SR new drug application (NDA). Ron Cohen, president
According to Novagali Pharma, Catioprost is a topical ocular proprietary BAK-free formulation of latanoprost which furthermore benefits from the ocular surface protection properties of Novasorb, its patented technology
Under the commercial agreement, the Consortium will explore production of MVA85A using the ProBioGen AGE1.CR.pIXA cell line, which was developed to replace chicken embryonic fibroblasts and chicken eggs
Under the commercial agreement, the Consortium will explore production of MVA85A using the Vivalis EB66 cell line, which is derived from duck embryonic stem cells. This cell line
Initially Ocimum will service gene expression studies on the Affymetrix platform from its facility at IJsselstein, The Netherlands. Within a couple of months, it will launch the entire